The autologous stem cell and non-stem cell based therapies market involves product segments comprising autologous stem cell therapies and non-stem cell based therapies. Autologous stem cell therapies utilize stem cells collected from the patient's own body for therapeutic applications whereas non-stem cell based therapies are personalized medicine approaches which do not involve the use of stem cells. These therapies are used for treating a variety of indications including musculoskeletal disorders, wound healing, cardiovascular diseases, oncology, and others.
The Global autologous stem cell and non-stem cell based therapies market is estimated to be valued at US$ 98.8 Bn in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the autologous stem cell and non-stem cell based therapies are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. Key players are focusing on clinical research and development of autologous stem cell therapies for various disease indications to strengthen their market presence.
The autologous stem cell and non-stem cell based therapies market is driven by the growing demand for personalized medicine approaches. Personalized therapies are more effective than traditional medication as they are developed specifically for an individual patient's genetic makeup and clinical condition. This drives the demand for autologous stem cell and non-stem cell based therapies.
Globally, the market for autologous stem cell and non-stem cell based therapies is expected to witness significant expansion during the forecast period. Several market players are investing heavily in R&D activities and focusing on geographical expansion including emerging markets to tap the increasing patient pool globally. Rising healthcare expenditures and improving access to healthcare facilities in developing nations will further support the global expansion of the autologous stem cell and non-stem cell based therapies market during the forecast years.
Market Key Trends
The autologous stem cell and non-stem cell based therapies market is undergoing trend of embracing combination therapies. Combination of autologous stem cell therapy with non-stem cell based therapy methods is gaining traction as it enhances therapeutic efficacy. The combination therapy approach leverages the advantages of both stem cells and other personalized medicine techniques to achieve optimum clinical outcomes. This emerging trend is expected to fuel market growth as combination therapies will likely become the future of personalized treatment of complex diseases.
Porter’s Analysis
Threat of new entrants: High capital investment required acts as a barrier.
Bargaining power of buyers: Buyers have low bargaining power due to availability of few substitutes.
Bargaining power of suppliers: Suppliers of raw materials have moderate bargaining power due to availability of alternatives.
Threat of new substitutes: Threat is moderate as new regenerative therapies can be potential substitutes.
Competitive rivalry: Intense competition exists between established players to develop advanced therapies.
Geographical Regions
North America accounts for the largest share in the autologous stem cell and non-stem cell based therapies market in terms of value, exceeding USD 36 Bn in 2023. This is attributed to increasing research funding, developed healthcare infrastructure, and rising burden of diseases in the region.
Asia Pacific is poised to grow at the fastest pace during the forecast period, expanding at a CAGR of over 5%. Growing healthcare expenditure, rising initiatives by local governments to develop medical tourism, and expanding patient pool are some of the factors driving the market in Asia Pacific.
No comments:
Post a Comment